The latest price target for NeuroPace (NASDAQ:NPCE) was reported by UBS on January 21, 2025. The analyst firm set a price target for $17.00 expecting NPCE to rise to within 12 months (a possible 12.43% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for NeuroPace (NASDAQ:NPCE) was provided by UBS, and NeuroPace initiated their buy rating.

The last upgrade for NeuroPace Inc happened on March 14, 2024 when Wells Fargo raised their price target to $20. Wells Fargo previously had an equal-weight for NeuroPace Inc.

There is no last downgrade for NeuroPace.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroPace, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroPace was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest NeuroPace (NPCE) rating was a initiated with a price target of $0.00 to $17.00. The current price NeuroPace (NPCE) is trading at is $15.12, which is within the analyst’s predicted range.